Serge Belanger

Stock Analyst at Needham

(4.75)
# 640
Out of 4,596 analysts
952
Total ratings
50.1%
Success rate
14%
Average return

Stocks Rated by Serge Belanger

Ocular Therapeutix
Aug 3, 2026
Maintained: Buy
Price Target: $18
Current: $8.38
Upside: +114.93%
Oculis Holding AG
Aug 3, 2026
Maintained: Buy
Price Target: $38
Current: $11.90
Upside: +219.33%
Cytokinetics
Jul 30, 2026
Maintained: Buy
Price Target: $102
Current: $76.42
Upside: +33.47%
Omeros
Jul 27, 2026
Maintained: Hold
Price Target: n/a
Current: $12.54
Upside: -
Pacira BioSciences
Jul 27, 2026
Maintained: Buy
Price Target: $32
Current: $26.88
Upside: +19.05%
NewAmsterdam Pharma Company
Jul 24, 2026
Maintained: Buy
Price Target: $48
Current: $27.38
Upside: +75.31%
Trevi Therapeutics
Jul 17, 2026
Maintained: Buy
Price Target: $23
Current: $17.93
Upside: +28.28%
Veradermics
Jul 15, 2026
Rated: Buy
Price Target: $136$164
Current: $101.00
Upside: +62.38%
Amphastar Pharmaceuticals
Jul 8, 2026
Maintained: Hold
Price Target: n/a
Current: $20.22
Upside: -
Evolus
Jul 8, 2026
Maintained: Hold
Price Target: n/a
Current: $6.04
Upside: -
Maintained: Buy
Price Target: $16
Current: $8.82
Upside: +81.51%
Maintained: Buy
Price Target: $36
Current: $25.84
Upside: +39.35%
Maintained: Buy
Price Target: $32$34
Current: $19.31
Upside: +76.12%
Maintained: Buy
Price Target: $30
Current: $17.42
Upside: +72.22%
Downgraded: Hold
Price Target: n/a
Current: $0.5168
Upside: -
Maintained: Buy
Price Target: $15
Current: $7.55
Upside: +98.81%
Rated: Hold
Price Target: n/a
Current: $5.12
Upside: -
Maintained: Buy
Price Target: $56
Current: $35.43
Upside: +58.08%
Maintained: Buy
Price Target: $54$70
Current: $83.86
Upside: -16.53%
Maintained: Buy
Price Target: $80$78
Current: $62.37
Upside: +25.06%
Rated: Hold
Price Target: n/a
Current: $1.32
Upside: n/a
Rated: Hold
Price Target: n/a
Current: $0.75
Upside: n/a
Maintained: Buy
Price Target: $22
Current: $2.16
Upside: n/a
Reiterated: Hold
Price Target: n/a
Current: $0.007
Upside: n/a
Reiterated: Buy
Price Target: $11$5
Current: $0.078
Upside: n/a